Medtronic Announces U.S. Commercial Launch of Solitaire X Revascularization Device in US

Medtronic plc is among the vital players operating in medical technology, services, and solutions industry. The company has four major business segments such as cardiac and vascular group, minimally invasive therapies groups, restorative therapies group, and group. The company has a presence in more than 150 countries across the world, and it serves its primary customers such as hospitals, clinics, third-party health care providers, distributors, and institutions, among others.

On January 26, 2015, the companies such as Medtronic, Inc., Minnesota corporation and Covidien plc became subsidiaries of Medtronic plc. The company has a wide range of product portfolio, and in the neurovascular devices the company offers is a product under the segment restorative therapies group. The segment provides products such as intra-operative imaging systems, image-guided surgery, robotic guidance systems, robot-assisted spine procedures.

The company also manufactures products for therapies that are used to treat diseases of the vasculature in the brain and around its periphery. The products include coils, flow diversion products, and neurovascular stent retrievers. The company was able to generate US$ 8.2 billion for the fiscal year 2019 from its restorative therapies group. Also, it noted a nearly 6% increase in the net sale of restorative therapies group.